Integrating molecular profiling into glioma diagnosis: implications of the WHO-CNS5-2021 classification of adult-type diffuse gliomas in Colombian patients
We highlight the importance of incorporating molecular methods to improve diagnostic accuracy and achieve personalized treatments for gliomas, as proposed by the current 2021 WHO CNS 5 tumor classification guidelines. Performing new studies with larger patient cohorts integrating clinical data is necessary to determine the behavior, epidemiology, and therapeutic outcomes of this type of tumor more comprehensively.
Authors
- Nora Soto Contreras
- Nicolás Caballero
- Alejandro Ondo-Méndez (ORCID: https://orcid.org/0000-0003-2473-8790)
- Ana Chinchilla
- Fonseca-Mendoza Dora Janeth
- Andrés Felipe Patiño-Aldana (ORCID: https://orcid.org/0000-0001-6017-3788)
- Omar Echeverría (ORCID: https://orcid.org/0009-0000-6753-0178)
- Nattaly Valero
- Hanna Valentina Tovar
- Verónica Uribe
- José Manuel Palacio (ORCID: https://orcid.org/0009-0005-9383-1288)
- Fernando Velandia
- Stevan Peralta
- Matteo Mineo-Pachón
- William Mauricio Riveros Castillo
- Daniel Felipe Silgado-Guzmán
Institutions
- Hospital Universitario de la Samaritana (CO)
- Universidad del Rosario (CO)
Publication Details
- Journal
- Frontiers in Neurology
- Published
- 2026-01-06
- DOI
- https://doi.org/10.3389/fneur.2025.1691983
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00